Ovid Therapeutics Inc. SEC Filings

Ovid Therapeutics Inc. has a significant holder reporting updated passive ownership. ADAR1 Capital Management, LLC and its manager Daniel Schneeberger report beneficial ownership of 9,559,979 shares of Ovid common stock, representing 5.1% of the class, all with shared voting and dispositive power. This stake includes 6,980,088 common shares held by ADAR1 Partners, LP, 435,032 shares held by Spearhead Insurance Solutions IDF, LLC, 2,359 shares held in separately managed accounts and 2,142,500 shares underlying warrants held by ADAR1 Partners, LP that are subject to 9.99% beneficial ownership limitations.

ADAR1 Capital Management GP, LLC, as general partner of ADAR1 Partners, LP, reports beneficial ownership of 9,122,588 shares, or 4.9% of the class, and characterizes this amendment as an exit filing solely for ADAR1 General Partner after falling below the 5% threshold. Ownership is calculated based on 184,755,735 Ovid common shares outstanding as of June 30, 2026.

RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and managers Peter Kolchinsky and Rajeev Shah report beneficial ownership of up to 19,549,271 shares of Ovid Therapeutics common stock as of June 30, 2026, representing 9.99% of the class. The Fund directly holds 10,500,968 shares plus pre-funded warrants for 5,013,426 shares and Series B warrants for 5,357,000 shares. Warrant “Beneficial Ownership Blockers” prevent exercises that would increase ownership above 9.99% of outstanding shares, limiting exercisability to 19,549,271 shares in total. Voting and dispositive power over the Fund’s holdings are delegated to RA Capital, and the reporting parties disclaim beneficial ownership except for determining obligations under Section 13(d) of the Act.

Eventide Asset Management, LLC and two affiliated individuals report a significant ownership position in Ovid Therapeutics Inc. As of June 30, 2026, Eventide, as investment adviser to the Eventide Healthcare & Life Sciences Fund, is the beneficial owner of 11,812,241 shares of Ovid’s common stock, representing 6.3% of the outstanding shares.

Eventide holds sole voting and dispositive power over these 11,812,241 shares, while Finny Kuruvilla, M.D., Ph.D. and Robin C. John have shared voting and dispositive power over the same amount. All three reporting parties jointly file this Schedule 13G/A and expressly disclaim beneficial ownership of the securities beyond what is attributable under applicable rules.

Balyasny Asset Management and related entities filed Amendment No. 1 to a Schedule 13G reporting their beneficial ownership in Ovid Therapeutics Inc. common stock.

The reporting group, including Balyasny Asset Management L.P., BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny, may be deemed to beneficially own 9,313,341 shares of Ovid common stock, representing 4.99% of the class, based on 186,640,102 shares outstanding as of May 8, 2026.

The position consists of 6,719,076 shares and 2,594,265 shares issuable upon exercise of 1,428,500 Series B Warrants and 1,496,150 Prefunded Warrants. The Series B Warrants are subject to a 4.99% Beneficial Ownership Limitation, and the Prefunded Warrants are subject to a 9.99% Second Beneficial Ownership Limitation, which cap ownership upon exercise at those levels.

Affinity Asset Advisors, LLC and Michael Cho, through Affinity Healthcare Fund, LP, report beneficial ownership of 15,143,728 shares of Ovid Therapeutics Inc. common stock as of June 30, 2026. This represents 7.9% of the outstanding common stock and includes 4,999,166 shares issuable upon exercise of warrants that are each subject to a 9.99% Beneficial Ownership Limitation. The reporting persons have sole voting and dispositive power over all 15,143,728 shares and no shared voting or dispositive power.

Ovid Therapeutics Inc. reported a larger loss for the quarter ended June 30, 2026 as it increased investment in its neurology pipeline. Revenue was $0.7 million, down sharply from $6.3 million a year earlier, primarily reflecting lower license and other revenue. Net loss for the quarter was $15.0 million versus $4.7 million in the prior-year quarter; for the first six months of 2026 the net loss was $32.0 million.

Operating expenses rose as programs advanced, with research and development spending reaching $10.0 million and general and administrative expenses $6.5 million in the quarter. The company strengthened its balance sheet through equity financings and warrant exercises, resulting in $110.6 million of net cash provided by financing activities in the first half of 2026.

As of June 30, 2026, Ovid held $169.8 million in cash, cash equivalents and marketable securities, up from $90.4 million at year-end 2025, and reported working capital of $113.6 million. Management states this liquidity is expected to fund current operations for at least 12 months from issuance of the financial statements.

Ovid Therapeutics Inc. reported second quarter 2026 results and extensive pipeline progress in neurology and psychiatry. The company is advancing OV4071, described as the first oral direct KCC2 activator, through an ongoing Phase 1 study in healthy volunteers, with data expected to support a Phase 2 schizophrenia proof‑of‑concept study in 2027 and a ketamine challenge study planned for the second half of 2026.

Ovid also initiated multiple Phase 2 and proof‑of‑concept studies for OV329, a next‑generation GABA‑AT inhibitor, across treatment‑resistant focal onset seizures, tuberous sclerosis complex–associated seizures and infantile spasms, with a global randomized FOS study targeting completion in the second half of 2027 and a photosensitivity study expecting results near year‑end 2026. A newly formed Perceptive Advisors–backed company acquired global rights to soticlestat, leaving Ovid eligible for up to $294.5 million in potential milestone payments plus low‑ to mid‑single digit royalties.

Liquidity strengthened meaningfully: cash, cash equivalents and marketable securities were $169.8 million as of June 30, 2026, and Ovid states this supports operations into 2029, helped by approximately $53.9 million of warrant‑exercise proceeds in April 2026. For the quarter, revenue was $0.7 million versus $6.3 million a year earlier, while net loss widened to $15.0 million from $4.7 million, driven by higher research and development and general and administrative expenses as clinical activity expanded.

BlackRock, Inc. reports a significant ownership position in Ovid Therapeutics Inc. common stock. BlackRock beneficially owns 10,822,672 shares of Ovid common stock, representing 5.8% of the outstanding class as of June 30, 2026.

BlackRock has sole voting power over 10,707,787 shares and sole dispositive power over 10,822,672 shares, with no shared voting or dispositive power. Various underlying clients have economic rights to dividends and sale proceeds, but no single client holds more than five percent of Ovid’s total outstanding common shares.

Carter Charles Ross reported acquisition or exercise transactions in this Form 4 filing.

Ovid Therapeutics Inc. reported that Chief Financial Officer Charles Ross received a grant of 50,000 restricted stock units (RSUs) of common stock on July 6, 2026 as equity compensation. Each RSU represents a contingent right to receive one share of common stock at no purchase price.

The RSUs will vest in two equal annual installments beginning on July 6, 2027, subject to Ross’s continuous service through each vesting date. Following this award, Ross directly holds 94,375 shares of Ovid common stock, reflecting his equity stake in the company.